Showing results (61-70 of 121) with videos related to

Sort By:
Pageof 13
Oncotarget|July 9, 2014
A virtual screen identified C96 as a novel inhibitor of phosphatidylinositol 3-kinase that displays potent preclinical activity against multiple myeloma in vitro and in vivoJuan Tang, Jingyu Zhu, Yang Yu, et al.
Cell Death & Disease|May 8, 2021
Suppression of USP7 induces BCR-ABL degradation and chronic myelogenous leukemia cell apoptosisShuoyi Jiang, Xiaoge Wang, Yuanming He, et al.
Anti-Cancer Drugs|August 15, 2018
A novel hedgehog inhibitor for the treatment of hematological malignanciesPeng Lin, Yuanming He, Guodong Chen, et al.
International Journal of Hematology|June 16, 2017
FLT3-ITD with DNMT3A R882 double mutation is a poor prognostic factor in Chinese patients with acute myeloid leukemia after chemotherapy or allogeneic hematopoietic stem cell transplantationShanhao Tang, Hongjie Shen, Xinliang Mao, et al.
International Journal of Cancer|February 25, 2012
A deuterated analog of dasatinib disrupts cell cycle progression and displays anti-non-small cell lung cancer activity in vitro and in vivoChunhua Ling, Gang Chen, Guodong Chen, et al.
Journal of Pharmacological Sciences|August 7, 2017
The Class I PI3K inhibitor S14161 induces autophagy in malignant blood cells by modulating the Beclin 1/Vps34 complexSiyu Wang, Jie Li, Yanyun Du, et al.
Cancer Cell International|November 2, 2013
PI3-kinase inhibition synergistically promoted the anti-tumor effect of lupeol in hepatocellular carcinomaFen Liu, Yan He, Yong Liang, et al.
Frontiers in Pharmacology|July 13, 2018
Saponins From Paris forrestii (Takht.) H. Li Display Potent Activity Against Acute Myeloid Leukemia by Suppressing the RNF6/AKT/mTOR Signaling PathwayQin Lu, Yuanming He, Yuehu Wang, et al.
The Journal of Biological Chemistry|February 23, 2018
The transmembrane protein TMEPAI induces myeloma cell apoptosis by promoting degradation of the c-Maf transcription factorYanyun Du, Yan Liu, Yujia Xu, et al.
Scientific Reports|September 3, 2015
SC06, a novel small molecule compound, displays preclinical activity against multiple myeloma by disrupting the mTOR signaling pathwayKunkun Han, Xin Xu, Zhuan Xu, et al.
Pageof 13